HomeCompareTHAR vs KO

THAR vs KO: Dividend Comparison 2026

THAR yields 57.64% · KO yields 2.70%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 THAR wins by $545.8K in total portfolio value
10 years
THAR
THAR
● Live price
57.64%
Share price
$3.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$579.9K
Annual income
$131,396.64
Full THAR calculator →
KO
The Coca-Cola Company
● Live price
2.70%
Share price
$76.27
Annual div
$2.06
5Y div CAGR
24.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.1K
Annual income
$4,303.79
Full KO calculator →

Portfolio growth — THAR vs KO

📍 THAR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTHARKO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, THAR + KO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
THAR pays
KO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

THAR
Annual income on $10K today (after 15% tax)
$4,899.14/yr
After 10yr DRIP, annual income (after tax)
$111,687.14/yr
KO
Annual income on $10K today (after 15% tax)
$229.58/yr
After 10yr DRIP, annual income (after tax)
$3,658.22/yr
At 15% tax rate, THAR beats the other by $108,028.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of THAR + KO for your $10,000?

THAR: 50%KO: 50%
100% KO50/50100% THAR
Portfolio after 10yr
$307.0K
Annual income
$67,850.21/yr
Blended yield
22.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KO right now

THAR
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
0.4
Piotroski
2/9
KO
Analyst Ratings
29
Buy
16
Hold
3
Sell
Consensus: Buy
Price Target
$84.88
+11.3% upside vs current
Range: $81.00 — $88.00
Altman Z
5.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

THAR buys
0
KO buys
0
No recent congressional trades found for THAR or KO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTHARKO
Forward yield57.64%2.70%
Annual dividend / share$2.00$2.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%24.3%
Portfolio after 10y$579.9K$34.1K
Annual income after 10y$131,396.64$4,303.79
Total dividends collected$477.1K$15.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy

Year-by-year: THAR vs KO ($10,000, DRIP)

YearTHAR PortfolioTHAR Income/yrKO PortfolioKO Income/yrGap
1← crossover$16,464$5,763.69$10,846$335.73+$5.6KTHAR
2$26,485$8,868.37$11,829$430.64+$14.7KTHAR
3$41,671$13,332.91$12,988$555.50+$28.7KTHAR
4$64,194$19,605.90$14,372$721.34+$49.8KTHAR
5$96,915$28,226.79$16,049$944.01+$80.9KTHAR
6$143,525$39,826.39$18,114$1,246.74+$125.4KTHAR
7$208,694$55,122.07$20,702$1,664.24+$188.0KTHAR
8$298,210$74,907.23$24,008$2,249.48+$274.2KTHAR
9$419,119$100,035.01$28,317$3,085.19+$390.8KTHAR
10$579,854$131,396.64$34,065$4,303.79+$545.8KTHAR

THAR vs KO: Complete Analysis 2026

THARStock

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Full THAR Calculator →

KOConsumer Staples

The Coca-Cola Company, a beverage company, manufactures, markets, and sells various nonalcoholic beverages worldwide. The company provides sparkling soft drinks, sparkling flavors; water, sports, coffee, and tea; juice, value-added dairy, and plant-based beverages; and other beverages. It also offers beverage concentrates and syrups, as well as fountain syrups to fountain retailers, such as restaurants and convenience stores. The company sells its products under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero Sugar, caffeine free Diet Coke, Cherry Coke, Fanta Orange, Fanta Zero Orange, Fanta Zero Sugar, Fanta Apple, Sprite, Sprite Zero Sugar, Simply Orange, Simply Apple, Simply Grapefruit, Fresca, Schweppes, Thums Up, Aquarius, Ayataka, BODYARMOR, Ciel, Costa, Dasani, dogadan, FUZE TEA, Georgia, glacéau smartwater, glacéau vitaminwater, Gold Peak, Ice Dew, I LOHAS, Powerade, Topo Chico, AdeS, Del Valle, fairlife, innocent, Minute Maid, and Minute Maid Pulpy brands. It operates through a network of independent bottling partners, distributors, wholesalers, and retailers, as well as through bottling and distribution operators. The company was founded in 1886 and is headquartered in Atlanta, Georgia.

Full KO Calculator →
📬

Get this THAR vs KO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

THAR vs SCHDTHAR vs JEPITHAR vs OTHAR vs MAINTHAR vs PEPTHAR vs PGTHAR vs JNJTHAR vs MCD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.